Prelude Therapeutics

We are excited to announce our clinical collaboration with Merck to evaluate PRT3789, our investigational, highly selective, first-in-class SMARCA2 degrader, in combination with KEYTRUDA®, Merck’s anti-PD-1 therapy, in patients with SMARCA4-mutated cancers. Prelude will sponsor the clinical trial and Merck will provide KEYTRUDA.   “Through this collaboration of potentially complementary mechanisms, we may have the potential to positively impact clinical outcomes in patients harboring a SMARCA4 mutation, who have previously been known to have limited treatment options.,” says Jane Huang, M.D., Prelude President and Chief Medical Officer. To read today's press release, visit our website: https://lnkd.in/edfnsFyX

Our CEO, Kris Vaddi, Ph.D. will be at upcoming healthcare conferences this month. Details here https://lnkd.in/eXqd8_k6 The live webcast of the fireside chat at Jeffries on June 6th is available here (https://lnkd.in/enFZY6vF) and the company presentation at Goldman Sachs on June 12th, can be found here (https://lnkd.in/e47KWwfq)

Thank you The Innovation Space for having Prelude's CSO, Peggy Scherle, at #dedna24 to share information about Prelude and our focus on targeted therapies for oncology, including our SMARCA2 degrader program. To learn more about it, visit our website: https://lnkd.in/e77D8bnv

Thank you BioBreak for having our CEO Kris Vaddi, Ph.D. on the panel at your CEO Forum event. It was a great event! #Delawarebio #biotech #precisiononcology #cancerresearch

Next week, on Tuesday, May 14th at 1 p.m. ET, Prelude's CEO, Kris Vaddi, Ph.D. and CMO Jane Huang, M.D., will participate in a fireside chat at the Citizens JMP Life Sciences Conference taking place in New York. Use this link to watch the live webcast: https://lnkd.in/eJUSu8wA

Today, we announced financial results for the first quarter of 2024 and corporate update. Highlights include: First-in-class IV SMARCA2 degrader, PRT3789 and potentially best-in-class CDK9 inhibitor, PRT2527 remain on track to generate initial proof-of-concept data in 2024    New preclinical data presented at AACR 2024 included first characterization of PRT7732, a highly-selective, orally bioavailable SMARCA2 degrader   Operational leadership capabilities further strengthened by recent hires Chief Business Officer Sean Brusky and Senior Vice President, Investor Relations Robert Doody   Current cash runway into 2026 with $201.9 million in cash, cash equivalents and marketable securities as of March 31, 2024 To read the press release, visit out website: https://lnkd.in/ebA5WiSF

A spring clean-up at Delaware's Ronald McDonald House was a great way for our team to mark Earth Day 2024. #earthday2024 #DEBio #precisiononcology #volunteering

We are thrilled to welcome Sean Brusky as our new Chief Business Officer. Sean brings deep oncology market expertise, portfolio strategy, market access, medical affairs, partnering and commercial launch experience to #TeamPrelude as we work to advance our pipeline of precision medicines. Welcome to the team, Sean!

Today at the #AACR 2024 conference, we presented new preclinical data on our highly selective oral SMARCA2 degrader (PRT7732), our potentially best-in-class CDK9 inhibitor (PRT2527), and our next-generation oral CDK4/6 inhibitor (PRT3645). Read the press release and review the posters here: https://lnkd.in/ei2QjDer “These presentations demonstrate our core competencies in medicinal chemistry and cancer biology to optimize and deliver compounds to the clinic with the potential to succeed as differentiated first- and/or best-in-class new therapies,” said Andrew Combs, Ph.D., Chief Chemistry Officer at Prelude Therapeutics. Peggy Scherle, Ph.D., Chief Scientific Officer at Prelude, stated, “Advancement of our second highly selective SMARCA2 degrader strengthens Prelude’s leadership position in the emerging use of SMARCA2 protein degradation as a potential treatment option for underserved patients with cancer. With both a first-in-class IV SMARCA2 degrader, PRT3789, in Phase 1 clinical development and now our oral SMARCA2 degrader, PRT7732, expected to enter the clinic later this year, we believe these distinct modalities may offer new therapies for patients with SMARCA4 mutations.” #AACR #precisiononcology #Cancerresearch #SMARCA2

Today at the Barclays Healthcare Conference in Miami, Kris Vaddi, Ph.D. and Jane Huang, M.D., will participate in a fireside chat at 3:05 pm ET. The live webcast is available on our website here: https://lnkd.in/ehmhMuSZ